Estrogen and Hypermobile Ehlers-Danlos Syndrome: Understanding the Hormonal Influence on Symptoms Across the Lifespan

Hypermobile Ehlers-Danlos syndrome (hEDS) is the most common subtype of Ehlers-Danlos syndrome, yet many aspects of the condition remain poorly understood. One observation that clinicians and patients report consistently is this: symptoms often fluctuate during periods of hormonal change.

Puberty, the menstrual cycle, pregnancy, the postpartum period, and menopause are all times when individuals with hEDS may notice significant shifts in pain, joint stability, fatigue, and overall function. For many, these patterns go unrecognized for years.

While hormones do not cause hEDS, emerging research suggests they may influence how the condition manifests. Estrogen and relaxin, in particular, appear to interact with connective tissue, pain processing, and autonomic regulation in ways that may shape symptom severity in hypermobile Ehlers-Danlos syndrome across the lifespan.

Understanding these relationships can help patients recognize patterns in their own experience and support clinicians in providing more individualized care.

What Is Hypermobile Ehlers-Danlos Syndrome (hEDS)?

Hypermobile Ehlers-Danlos syndrome is a hereditary connective tissue disorder characterized by generalized joint hypermobility, musculoskeletal pain, joint instability, and a variety of extra-articular manifestations. Unlike other EDS subtypes, the specific genetic cause of hEDS has not yet been identified.

Common features include:

•  Joint hypermobility

• Frequent sprains, subluxations, or dislocations

• Chronic pain

• Fatigue

• Soft or mildly hyperextensible skin

• Gastrointestinal symptoms

• Pelvic floor dysfunction

• Autonomic dysfunction, including postural orthostatic tachycardia syndrome (POTS)

The current diagnostic criteria can be found through the Ehlers-Danlos Society hEDS diagnostic checklist.

Why Hormones Matter in Hypermobile EDS

• Sex hormones influence numerous physiological processes throughout the body, including:

• Collagen production and metabolism

• Ligament stiffness and tendon elasticity

• Bone metabolism

• Vascular function

• Inflammatory pathways

• Pain perception and modulation

Because connective tissue abnormalities are central to hEDS, hormonal changes may have a greater impact in this population than in the general population.

Many women with hEDS report worsening symptoms at predictable times throughout their reproductive lifespan. Although the exact mechanisms remain unclear, research increasingly supports the idea that hormones and hypermobility interact in clinically meaningful ways, contributing to symptom expression and flare patterns.

How Estrogen Affects Connective Tissue and Joint Stability

Estrogen has complex effects on ligaments and tendons. Research suggests that 17-beta-estradiol, the predominant form of estrogen during reproductive years, can influence collagen metabolism and the mechanical properties of connective tissues.

Studies have demonstrated that estrogen effects on connective tissue may include:

• Decreased collagen synthesis under certain conditions

• Altered collagen fibril organization

• Reduced tendon and ligament stiffness

• Changes to the extracellular matrix through matrix metalloproteinase (MMP) activity

These effects may increase tissue flexibility. In the general population, this can sometimes be beneficial. However, in individuals who already have underlying connective tissue fragility, further reductions in ligament stiffness may contribute to instability.

A systematic review examining estrogen's influence on musculoskeletal tissues found that sex hormones affect tendon and ligament properties and may influence injury risk. Chidi-Ogbolu N, Baar K. Effect of Estrogen on Musculoskeletal Performance and Injury Risk. Frontiers in Physiology. 2019.

Importantly, estrogen deficiency and chronic pain also have a well-documented relationship. Estrogen does not create hEDS. Rather, it may modify how symptoms are experienced across the lifespan.

Relaxin, Joint Laxity, and Hypermobility

Relaxin is another hormone relevant in hEDS.

Produced primarily during pregnancy, relaxin facilitates connective tissue remodeling to accommodate childbirth. It also fluctuates throughout the menstrual cycle.

Relaxin can activate matrix metalloproteinases (MMPs), enzymes involved in extracellular matrix breakdown and remodeling. Increased relaxin activity has been associated with increased ligamentous laxity.

Research has demonstrated that elevated relaxin levels may correlate with increased anterior-posterior joint laxity and may be associated with higher risk of ligament injury in female athletes.

For individuals with hEDS, whose connective tissues may already be more vulnerable, these hormonal effects on joint stability could potentially amplify instability during periods of elevated relaxin. More research specifically examining relaxin and joint laxity in hEDS populations is needed.

Hormonal Changes Throughout the Lifespan in hEDS

A study by Hugon-Rodin and colleagues evaluated gynecologic symptoms in women with hEDS and hypermobility spectrum disorders. The authors found that a subset of women reported symptom fluctuations associated with hormonal changes, most often worsening during puberty, the premenstrual phase, pregnancy, the postpartum period, and with hormonal contraceptive use.

Reference: Hugon-Rodin J, et al. Gynecologic symptoms and the influence on reproductive life in women with Ehlers-Danlos syndrome. American Journal of Medical Genetics Part A. 2016.

These findings highlight the importance of asking patients whether symptom patterns correspond with hormonal transitions.

Puberty and Hypermobile EDS

Puberty is often the first major hormonal transition at which hEDS symptoms become more pronounced. Rising estrogen levels, combined with growth-related changes in musculoskeletal demands, may contribute to increased pain, joint instability, and fatigue during this period.

Menstrual Cycle and hEDS Symptom Changes

Many individuals with hEDS report worsening pain, fatigue, and instability during certain phases of the menstrual cycle, particularly in the premenstrual phase when estrogen levels drop. Symptom fluctuations tied to the menstrual cycle are among the most commonly reported patterns in this population.

Pregnancy and Hypermobile EDS

Pregnancy introduces significant hormonal changes, including substantial increases in relaxin and estrogen. For individuals with hEDS, pregnancy and hypermobile EDS interact in ways that may amplify joint laxity, pelvic pain, and musculoskeletal instability.

Pregnancy-related complications reported in the literature include increased pelvic girdle pain, symphysis pubis dysfunction, and greater demand on already-compromised support structures. Prenatal physical therapy focused on load management and joint stability may be an important part of care during this period.

Postpartum Recovery

The postpartum period can be particularly challenging for individuals with hEDS. Relaxin levels remain elevated for some time after delivery, and the physical demands of caring for a newborn occur alongside a body that may still be recovering from the destabilizing effects of pregnancy hormones.

Pelvic floor dysfunction in EDS is especially relevant postpartum. Early referral to pelvic floor physical therapy may help address symptoms of instability, prolapse risk, and pain during this transition.

Perimenopause and Menopause

Perimenopause introduces irregular and often dramatic hormonal fluctuations before estrogen levels ultimately decline with menopause. Many women with hEDS report this as one of the most unpredictable periods in their symptom history.

Unlike the more consistent hormonal patterns of the reproductive years, perimenopause does not follow a predictable rhythm. Symptoms that were previously manageable may become harder to anticipate. This is not a sign that something has gone wrong in the management plan. It often reflects the instability of the hormonal environment itself.

Hormones, POTS, and Dysautonomia

Hormonal fluctuations do not only affect connective tissue. They also interact with the autonomic nervous system, which is already a common area of dysfunction in hEDS.

Many women with hEDS describe a predictable pattern: symptoms that were manageable for most of the month become significantly harder to tolerate in the days before a period, or shift substantially during perimenopause. What they are often describing is not just musculoskeletal change. They are describing autonomic instability that tracks with hormonal cycles.

Women with POTS and dysautonomia frequently report worsening symptoms during certain phases of the menstrual cycle and during the menopause transition. This may manifest as:

• Increased tachycardia or heart rate variability

• Worsening dizziness or lightheadedness

• Greater blood pooling and orthostatic intolerance

• Fatigue that does not correlate with activity level

• Worsening brain fog

  
  

Estrogen appears to influence vascular tone, blood volume regulation, and autonomic signaling. As estrogen and dysautonomia interact, fluctuations in hormone levels may destabilize an autonomic nervous system that is already operating with reduced reserve.

This is one reason why symptom patterns in hEDS often feel cyclical or unpredictable.

They may be, in part, tracking hormonal shifts that alter autonomic stability as much as they alter connective tissue behavior.

Gynecologic Symptoms Common in Women With hEDS

Gynecologic symptoms appear to be common among women with hEDS and are frequently underrecognized.

• In the Hugon-Rodin cohort, participants frequently reported:

• Menorrhagia (heavy menstrual bleeding in EDS)

• Dysmenorrhea (painful menstruation)

• Dyspareunia (pain during intercourse)

• Pregnancy-related complications

• Miscarriage

Heavy menstrual bleeding in EDS may result from multiple contributing factors, including vascular fragility and connective tissue abnormalities affecting uterine support structures.

Because symptoms such as pelvic pain and heavy bleeding overlap with other gynecologic conditions, careful evaluation is essential. Symptoms should not automatically be attributed to hEDS alone.

Menopause and Hypermobile EDS

Menopause introduces another significant hormonal transition, and its effects on hEDS are not straightforward.

As estrogen levels decline, some women may notice reduced ligamentous laxity. Joint hypermobility scores often decrease with age, and estrogen withdrawal may contribute to this change. For some individuals, this represents a welcome reduction in instability.

However, menopause may also worsen other aspects of hEDS. Estrogen deficiency has been associated with:

• Osteoarthritis progression

• Osteoporosis

• Sarcopenia (loss of muscle mass)

• Increased chronic pain

• Worsening central sensitization

Estrogen also exerts anti-inflammatory and chondroprotective effects. The loss of these protective mechanisms during menopause may compound preexisting musculoskeletal challenges. Some evidence also suggests that declining estrogen levels may worsen nociceptive, neuropathic, and central sensitization-related pain pathways.

The menopause transition may therefore improve certain aspects of hEDS while exacerbating others, and the experience is highly individual.

Pelvic Floor Dysfunction After Menopause

Pelvic floor dysfunction is already common in hEDS due to connective tissue fragility. Following menopause, declining estrogen levels may contribute to tissue atrophy and further compromise pelvic support structures.

• Potential consequences include:

• Stress urinary incontinence

• Pelvic organ prolapse

• Sexual dysfunction

• Increased pelvic pain

  
  

Given these risks, early recognition and referral to pelvic floor physical therapy may be beneficial. Perimenopause and hypermobility is a period worth addressing proactively rather than reactively.

Hormonal Treatments and Hypermobile EDS

At present, evidence supporting hormonal treatments specifically for hEDS remains limited.

Some individuals report symptom improvement with hormonal modulation, while others experience worsening instability or pain. Potential benefits of hormonal therapies may include:

• Improved control of heavy menstrual bleeding

• Management of menopausal vasomotor symptoms

• Bone protection in appropriate candidates

• Possible pain modulation

However, there are theoretical concerns that exogenous estrogen could increase connective tissue laxity in susceptible individuals. Currently, no randomized controlled trials have evaluated menopausal hormone therapy specifically in women with hEDS.

Decisions regarding hormonal contraception or hormone therapy and EDS should be individualized and made collaboratively with a knowledgeable healthcare provider.

Current Management Recommendations

Despite increasing interest in hormonal influences, current hEDS management guidelines do not include specific hormonal recommendations.

Management continues to emphasize:

• Physical therapy focused on stability and proprioception

• Occupational therapy when appropriate

• Pain management strategies

• Psychological support

• Self-management education

• Treatment of comorbid conditions including POTS and pelvic floor dysfunction

The Ehlers-Danlos Society management resources for healthcare professionals provide additional guidance on current clinical approaches.

Healthcare providers should recognize that hEDS symptoms may fluctuate during periods of hormonal transition. Understanding these patterns may help validate patients' experiences and support more personalized treatment planning.

Frequently Asked Questions

How does estrogen affect hypermobile Ehlers-Danlos syndrome?

Estrogen influences collagen metabolism, ligament stiffness, pain processing, and connective tissue function through multiple pathways. In some people with hEDS, hormonal fluctuations may contribute to symptom changes and joint instability, particularly during the menstrual cycle, pregnancy, and menopause.

Why do hEDS symptoms get worse during my period?

Many individuals with hEDS report increased pain, fatigue, and instability during certain phases of the menstrual cycle, particularly in the premenstrual phase when estrogen levels drop. The exact mechanisms are not fully understood, but hormonal effects on connective tissue laxity and pain modulation pathways are likely contributors.

Does pregnancy affect hypermobile EDS symptoms?

Pregnancy-related increases in hormones such as relaxin may contribute to increased joint laxity, pelvic pain, and musculoskeletal symptoms in some individuals with hEDS. The postpartum period can also be challenging as the body recovers from these hormonal changes while managing increased physical demands.

Can menopause change hypermobility symptoms?

Yes. Some women experience reduced joint laxity after menopause as estrogen levels decline. However, others notice increased pain, pelvic floor dysfunction, or musculoskeletal challenges related to estrogen deficiency. The experience is highly individual and the relationship between menopause and hypermobile EDS is not straightforward.

Is hormone replacement therapy recommended for hEDS?

Currently, there are no specific hormone therapy guidelines for hEDS. Decisions regarding hormonal treatment should be individualized and discussed with a knowledgeable healthcare provider who is familiar with connective tissue disorders.

How do hormones affect POTS in hEDS?

Estrogen influences vascular tone, blood volume, and autonomic signaling. Many women with POTS and hormonal changes report worsening dysautonomia symptoms during certain phases of the menstrual cycle and during perimenopause, including increased tachycardia, dizziness, blood pooling, and fatigue.

Key Takeaways on Estrogen and Hypermobile EDS

The molecular basis of hEDS remains incompletely understood, and the precise mechanisms by which estrogen influences symptom expression have yet to be fully elucidated.

What we do know is that many individuals with hEDS experience meaningful symptom fluctuations during times of hormonal change. Estrogen and relaxin likely interact with connective tissue, pain pathways, autonomic regulation, and reproductive health in ways that shape the clinical presentation of hEDS throughout life.

More high-quality research is needed to determine how hormonal factors influence disease burden, treatment outcomes, and long-term health in hypermobile Ehlers-Danlos syndrome.

Until then, recognizing these patterns and incorporating them into clinical decision-making may provide an important step toward more personalized, patient-centered care.

If your symptoms have always seemed to track with your cycle, your pregnancy, or a hormonal shift you could not quite explain, you are not imagining it. Talk to one of our EDS-informed specialists - the first conversation is free.

Disclaimer: This article is intended for educational purposes only and should not be considered medical advice. Individuals experiencing changes in symptoms related to hormonal transitions should discuss their concerns with their physician or other qualified healthcare provider.